Oncology

The FDA approved oral decitabine and cedazuridine (Inqovi) tablets with venetoclax for adults with newly diagnosed acute myeloid leukemia who are aged 75 years or older or have comorbidities that preclude...

The FDA approved Bizengri for adults with advanced, unresectable, or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy, providing a new targeted option for an ultra-rare and...

In an open-label, multicenter phase 2 study, frontline mantle cell lymphoma, MRD-driven acalabrutinib-lenalidomide anti-CD20 therapy produced high molecular complete response rates.

In phase 1/2 BRUIN, most patients with CLL/SLL or MCL had stable or improved PROs during pirtobrutinib treatment.

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...

In a multicenter cohort, post-oophorectomy HRT was not linked to higher breast cancer risk in women with BRCA variants.

The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.

The FDA has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for adults and pediatric patients aged 12 years and older with previously untreated stage III or IV...